Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study).

36 We observed an increase in the proportion of subjects achieving the MCID composite endpoints for the cell-treated groups compared with the sham at month 12 but did not reach statistical significance, related to the high level of placebo effect.

also in 111,027 other papers